BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, Miller C. A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients. Infect Dis Ther. 2015; Jan 28. [Epub ahead of print]. [PMID: 25708155 DOI: 10.1007/s40121-015-0058-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Hudson B, Walker AJ, Irving WL. Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK. J Med Virol 2017;89:2158-64. [PMID: 28480974 DOI: 10.1002/jmv.24848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
2 Ahmed A, Schriever C, Britt N, Yager J, Amin R, McGuey L, Patel N. Comparing drug interaction frequencies of various hepatitis C treatment regimens among monoinfected patients. Ann Hepatol 2019;18:601-6. [PMID: 31078440 DOI: 10.1016/j.aohep.2019.01.005] [Reference Citation Analysis]
3 McCoy TH, Castro VM, Cagan A, Snapper L, Roberson A, Perlis RH. Cytochrome P450 interactions are common and consequential in Massachusetts hospital discharges. Pharmacogenomics J 2018;18:347-50. [PMID: 28696416 DOI: 10.1038/tpj.2017.30] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Schulte B, Wübbolding M, Marra F, Port K, Manns MP, Back D, Cornberg M, Stichtenoth DO, Höner Zu Siederdissen C, Maasoumy B. Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. Open Forum Infect Dis 2020;7:ofaa040. [PMID: 32104719 DOI: 10.1093/ofid/ofaa040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Smolders EJ, de Kanter CT, de Knegt RJ, van der Valk M, Drenth JP, Burger DM. Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications. Clin Pharmacokinet 2016;55:1471-94. [PMID: 27317413 DOI: 10.1007/s40262-016-0407-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
6 Marra F, Höner Zu Siederdissen C, Khoo S, Back D, Schlag M, Ouwerkerk-Mahadevan S, Bicer C, Lonjon-Domanec I, Jessner W, Beumont-Mauviel M, Kalmeijer R, Cornberg M. Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. Br J Clin Pharmacol 2018;84:961-71. [PMID: 29345798 DOI: 10.1111/bcp.13519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Noor S, Ismail M, Khan F. Potential Drug-Drug Interactions in Patients With Urinary Tract Infections: A Contributing Factor in Patient and Medication Safety. Front Pharmacol 2019;10:1032. [PMID: 31607905 DOI: 10.3389/fphar.2019.01032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Dissegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One 2017;12:e0172159. [PMID: 28245248 DOI: 10.1371/journal.pone.0172159] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
9 Noor S, Ismail M, Haider I, Khadim F. Drug-Drug Interactions in Hepatitis Patients: Do these Interactions Matter in Clinical Perspectives? Annals of Hepatology 2018;17:1001-11. [DOI: 10.5604/01.3001.0012.7200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Smolders EJ, Berden FA, de Kanter CT, Kievit W, Drenth JP, Burger DM. The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions. United European Gastroenterol J 2017;5:648-57. [PMID: 28815028 DOI: 10.1177/2050640616678151] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
11 Noor S, Ismail M, Khadim F. Potential drug-drug interactions associated with adverse clinical outcomes and abnormal laboratory findings in patients with malaria. Malar J 2020;19:316. [PMID: 32867788 DOI: 10.1186/s12936-020-03392-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
12 Yang Y, Dang SS. Safety of direct antiviral agents for treatment of hepatitis C virus infection. Shijie Huaren Xiaohua Zazhi 2017; 25(8): 659-669 [DOI: 10.11569/wcjd.v25.i8.659] [Reference Citation Analysis]
13 Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, Chiu YL, Podsadecki TJ, Menon RM. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers. Clin Pharmacokinet 2016;55:1003-14. [PMID: 26895022 DOI: 10.1007/s40262-016-0373-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
14 Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin MA, Cuzin L, Billaud E, Cheret A, Rey D, Jacomet C, Duvivier C, Pugliese P, Pradat P, Cotte L; Hepadat'AIDS Study Group. Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. PLoS One 2015;10:e0141164. [PMID: 26488159 DOI: 10.1371/journal.pone.0141164] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]